{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:32:51Z","timestamp":1793363571939,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10549-021-06192-w","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:02:40Z","timestamp":1617620560000},"page":"149-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer"],"prefix":"10.1007","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-1717","authenticated-orcid":false,"given":"Nicol\u00f2 Matteo Luca","family":"Battisti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sol","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivatharshini","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mappouridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanthi","family":"Senthivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalaprapa","family":"Asavisanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli-Sophia","family":"Tripodaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily F.","family":"Goode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Stanway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-2973","authenticated-orcid":false,"given":"Alistair","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"issue":"13","key":"6192_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","volume":"381","author":"DF Hayes","year":"2019","unstructured":"Hayes DF (2019) HER2 and breast cancer: a phenomenal success story. N Engl J Med 381(13):1284\u20131286","journal-title":"N Engl J Med"},{"issue":"2","key":"6192_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22(2):322\u2013329","journal-title":"J Clin Oncol"},{"issue":"7","key":"6192_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95(7):1592\u20131600","journal-title":"Cancer"},{"issue":"10","key":"6192_CR4","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","volume":"122","author":"D Eiger","year":"2020","unstructured":"Eiger D, Pond\u00e9 NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS et al (2020) Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab Treatment Optimization Trial. Br J Cancer 122(10):1453\u20131460","journal-title":"Br J Cancer"},{"issue":"17","key":"6192_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293\u20131305","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"6192_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","volume":"31","author":"SM Ewer","year":"2008","unstructured":"Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31(6):459\u2013467","journal-title":"Drug Saf"},{"issue":"26","key":"6192_CR7","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","volume":"34","author":"C Guenancia","year":"2016","unstructured":"Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F et al (2016) Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 34(26):3157\u20133165","journal-title":"J Clin Oncol"},{"issue":"31","key":"6192_CR8","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792\u20133799","journal-title":"J Clin Oncol"},{"issue":"21","key":"6192_CR9","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"SD Russell","year":"2010","unstructured":"Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F et al (2010) Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28(21):3416\u20133421","journal-title":"J Clin Oncol"},{"issue":"11","key":"6192_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"25","key":"6192_CR11","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C et al (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25(25):3859\u20133865","journal-title":"J Clin Oncol"},{"key":"6192_CR12","first-page":"Cd006243","volume":"4","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al (2012) (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 4:Cd006243","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"6192_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","volume":"2","author":"C Dang","year":"2016","unstructured":"Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K et al (2016) Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2(1):29\u201336","journal-title":"JAMA Oncol"},{"issue":"2","key":"6192_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18(2):113\u2013119","journal-title":"J Card Fail"},{"issue":"29","key":"6192_CR15","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1200\/JCO.2016.71.4345","volume":"35","author":"KE Reeder-Hayes","year":"2017","unstructured":"Reeder-Hayes KE, Meyer AM, Hinton SP, Meng K, Carey LA, Dusetzina SB (2017) Comparative toxicity and effectiveness of trastuzumab-based chemotherapy regimens in older women with early-stage breast cancer. J Clin Oncol 35(29):3298\u20133305","journal-title":"J Clin Oncol"},{"issue":"1","key":"6192_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctrv.2012.03.009","volume":"39","author":"J Brollo","year":"2013","unstructured":"Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V et al (2013) Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 39(1):44\u201350","journal-title":"Cancer Treat Rev"},{"key":"6192_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1920","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"6192_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","volume":"100","author":"AL Jones","year":"2009","unstructured":"Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD et al (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100(5):684\u2013692","journal-title":"Br J Cancer"},{"key":"6192_CR19","volume-title":"Stata statistical software: release 16","author":"StataCorp.","year":"2019","unstructured":"StataCorp. (2019) Stata statistical software: release 16. StataCorp, College Station"},{"issue":"1","key":"6192_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","volume":"179","author":"E de Azambuja","year":"2020","unstructured":"de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M et al (2020) A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat 179(1):161\u2013171","journal-title":"Breast Cancer Res Treat"},{"issue":"10191","key":"6192_CR21","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","volume":"393","author":"HM Earl","year":"2019","unstructured":"Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L et al (2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 393(10191):2599\u20132612","journal-title":"Lancet"},{"issue":"9","key":"6192_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","volume":"32","author":"I Vaz-Luis","year":"2014","unstructured":"Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32(9):927\u2013934","journal-title":"J Clin Oncol"},{"issue":"4","key":"6192_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdr348","volume":"23","author":"C Serrano","year":"2012","unstructured":"Serrano C, Cort\u00e9s J, De Mattos-Arruda L, Bellet M, G\u00f3mez P, Saura C et al (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23(4):897\u2013902","journal-title":"Ann Oncol"},{"issue":"8","key":"6192_CR24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","volume":"11","author":"ML Henry","year":"2018","unstructured":"Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M (2018) Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging 11(8):1084\u20131093","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"6192_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/jcm10010154","volume":"10","author":"M Laufer-Perl","year":"2021","unstructured":"Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z (2021) The Role of speckle strain echocardiography in the diagnosis of early subclinical cardiac injury in cancer patients-is there more than just left ventricle global longitudinal strain? J Clin Med. 10(1):154","journal-title":"J Clin Med."},{"key":"6192_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1957","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"6192_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J et al (2021) Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 77(4):392\u2013401","journal-title":"J Am Coll Cardiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06192-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06192-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:32:53Z","timestamp":1624620773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06192-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6192"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06192-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-251663\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Battisti has received travel grants from Genomic Health and Pfizer and speaker fees from Pfizer and AbbVie. Dr. Lyon has received speaker, advisory board or consultancy fees and\/or research grants from Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Janssens-Cilag Ltd, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd. Dr. Ring has received advisory board and speaker fees from Roche, Novartis, Pfizer, MSD and Lilly. Dr. Andres, Dr. Lee, Dr Ramalingam, Dr. Nash, Dr Mappouridou, Dr. Senthivel, Dr. Asavisanu, Dr. Obeid, Dr. Tripodaki, Dr. Angelis, Dr. Fleming, Dr. Goode, Dr. John, Professor Rosen, Dr. Allen, Dr. Stanway have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This analysis was approved as a Service Evaluation by The Committee for Clinical Review of The Royal Marsden NHS Foundation Trust.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No individual person\u2019s data are included in the manuscript in any form and therefore no consents for publication were required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}